| Systemic therapy of metastasizing renal cell carcinoma | |
| | |
MedLine Citation:
|
PMID: 18825295 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Once surgical options have been exhausted, systemic therapy is indicated for metastasizing renal cell carcinoma. Until recently this was carried out using mainly immunotherapeutic concepts with unsatisfactory results. Since the majority of clear cell renal cell carcinomas are well vascularised, angiogenetic inhibition offered an alternative therapy goal. To date, four substances have been approved to control angiogenesis in the therapy of renal cell carcinoma: sunitinib, sorafenib, temsirolimus, as well as a combination of bevacizumab and interferon alpha. Other substances, such as everolimus, pazopanib and axitinib, are currently the subject of clinical trials. Initial data on tolerance and efficacy was presented at this years annual conference of the American Society of Clinical Oncology (ASCO). This article examines current therapy options and ASCO data and discusses future trends. |
| | |
Authors:
|
M Staehler; N Haseke; K Zilinberg; T Stadler; A Karl; C G Stief |
Publication Detail:
|
Type: English Abstract; Journal Article |
Journal Detail:
|
Title: Der Urologe. Ausg. A Volume: 47 ISSN: 0340-2592 ISO Abbreviation: Urologe A Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-09-30 Completed Date: 2009-01-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 1304110 Medline TA: Urologe A Country: Germany |
Other Details:
|
Languages: ger Pagination: 1357-67 Citation Subset: IM |
Affiliation:
|
Urologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Klinikum Grosshadern, Marchioninistrasse 15, 81377 München, Deutschland. michael.staehler@med.uni-muenchen.de |
Vernacular Title:
|
Systemische Therapie des metastasierten Nierenzellkarzinoms. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiogenesis Inhibitors
/
therapeutic use* Antibodies, Monoclonal / therapeutic use Benzenesulfonates / therapeutic use Carcinoma, Renal Cell / blood supply, drug therapy*, pathology, radiography Chemotherapy, Adjuvant Clinical Trials as Topic Disease Progression Drug Therapy, Combination Humans Indoles / therapeutic use Interferon-alpha / therapeutic use Kidney Neoplasms / blood supply, drug therapy*, pathology, radiography Pyridines / therapeutic use Pyrroles / therapeutic use Sirolimus / analogs & derivatives, therapeutic use Tomography, X-Ray Computed |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Benzenesulfonates; 0/Indoles; 0/Interferon-alpha; 0/Pyridines; 0/Pyrroles; 0/bevacizumab; 0/sorafenib; 0/sunitinib; 0/temsirolimus; 53123-88-9/Sirolimus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Anhydrous proton-conducting properties of triazole-phosphonic acid copolymers: a combined study with...
Next Document: Organochlorine pesticide and polychlorinated biphenyl in calves from north-west Spain.